New and Emerging Medical Therapies in Parkinson's Disease.
Identifieur interne : 000000 ( PubMed/Curation ); suivant : 000001New and Emerging Medical Therapies in Parkinson's Disease.
Auteurs : Mitesh Lotia [États-Unis] ; Joseph JankovicSource :
- Expert opinion on pharmacotherapy ; 2016.
Abstract
Parkinson's disease (PD) is one of the most challenging neurodegenerative disorders to treat as it manifests with a large variety of troublesome, and often disabling, motor and non-motor symptoms. Despite limitations, such as motor and other complications, levodopa remains the most effective drug in the treatment of PD. Areas covered: In this review, we focus on phase 2 and 3 studies describing new and emerging medical therapies in PD. We discuss new formulations of levodopa, medications that prolong levodopa response and ameliorate levodopa-induced dyskinesias, and innovative delivery methods that are currently being evaluated in clinical trials or are in development with the promise of better efficacy and tolerability. We also describe novel non-dopaminergic drugs that have been identified for treatment of motor and non-motor symptoms. A specific section is designated for potential disease modifying therapies. Expert Opinion: Alternative formulations of levodopa appear to be promising especially to help with the motor fluctuations either by providing sustained benefits with controlled released formulations or ameliorate sudden OFF by formulations such as inhaled levodopa. Several different medications affecting non-dopaminergic pathways are being evaluated which may aide levodopa. As the understanding of the disease grows further, numerous novel neuroprotective or disease modifying therapies have been suggested. This along with development of medications to treat various non-motor symptoms will help improve quality of life of patients with PD.
DOI: 10.1517/14656566.2016.1149163
PubMed: 26830844
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000000
Links to Exploration step
pubmed:26830844Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New and Emerging Medical Therapies in Parkinson's Disease.</title><author><name sortKey="Lotia, Mitesh" sort="Lotia, Mitesh" uniqKey="Lotia M" first="Mitesh" last="Lotia">Mitesh Lotia</name><affiliation wicri:level="1"><nlm:affiliation>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 , Email: mitesh.lotia@bcm.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 </wicri:regionArea></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="doi">10.1517/14656566.2016.1149163</idno><idno type="RBID">pubmed:26830844</idno><idno type="pmid">26830844</idno><idno type="wicri:Area/PubMed/Corpus">000000</idno><idno type="wicri:Area/PubMed/Curation">000000</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New and Emerging Medical Therapies in Parkinson's Disease.</title><author><name sortKey="Lotia, Mitesh" sort="Lotia, Mitesh" uniqKey="Lotia M" first="Mitesh" last="Lotia">Mitesh Lotia</name><affiliation wicri:level="1"><nlm:affiliation>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 , Email: mitesh.lotia@bcm.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 </wicri:regionArea></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="e-ISSN">1744-7666</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is one of the most challenging neurodegenerative disorders to treat as it manifests with a large variety of troublesome, and often disabling, motor and non-motor symptoms. Despite limitations, such as motor and other complications, levodopa remains the most effective drug in the treatment of PD. Areas covered: In this review, we focus on phase 2 and 3 studies describing new and emerging medical therapies in PD. We discuss new formulations of levodopa, medications that prolong levodopa response and ameliorate levodopa-induced dyskinesias, and innovative delivery methods that are currently being evaluated in clinical trials or are in development with the promise of better efficacy and tolerability. We also describe novel non-dopaminergic drugs that have been identified for treatment of motor and non-motor symptoms. A specific section is designated for potential disease modifying therapies. Expert Opinion: Alternative formulations of levodopa appear to be promising especially to help with the motor fluctuations either by providing sustained benefits with controlled released formulations or ameliorate sudden OFF by formulations such as inhaled levodopa. Several different medications affecting non-dopaminergic pathways are being evaluated which may aide levodopa. As the understanding of the disease grows further, numerous novel neuroprotective or disease modifying therapies have been suggested. This along with development of medications to treat various non-motor symptoms will help improve quality of life of patients with PD.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">26830844</PMID><DateCreated><Year>2016</Year><Month>2</Month><Day>2</Day></DateCreated><DateRevised><Year>2016</Year><Month>2</Month><Day>3</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2016</Year><Month>Feb</Month><Day>1</Day></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>New and Emerging Medical Therapies in Parkinson's Disease.</ArticleTitle><Pagination><MedlinePgn></MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Parkinson's disease (PD) is one of the most challenging neurodegenerative disorders to treat as it manifests with a large variety of troublesome, and often disabling, motor and non-motor symptoms. Despite limitations, such as motor and other complications, levodopa remains the most effective drug in the treatment of PD. Areas covered: In this review, we focus on phase 2 and 3 studies describing new and emerging medical therapies in PD. We discuss new formulations of levodopa, medications that prolong levodopa response and ameliorate levodopa-induced dyskinesias, and innovative delivery methods that are currently being evaluated in clinical trials or are in development with the promise of better efficacy and tolerability. We also describe novel non-dopaminergic drugs that have been identified for treatment of motor and non-motor symptoms. A specific section is designated for potential disease modifying therapies. Expert Opinion: Alternative formulations of levodopa appear to be promising especially to help with the motor fluctuations either by providing sustained benefits with controlled released formulations or ameliorate sudden OFF by formulations such as inhaled levodopa. Several different medications affecting non-dopaminergic pathways are being evaluated which may aide levodopa. As the understanding of the disease grows further, numerous novel neuroprotective or disease modifying therapies have been suggested. This along with development of medications to treat various non-motor symptoms will help improve quality of life of patients with PD.</AbstractText></Abstract><AuthorList><Author><LastName>Lotia</LastName><ForeName>Mitesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>a Fellow, Movement disorders, Parkinson's Disease Center and Movement Disorders Clinic , Department of Neurology Baylor College of Medicine , 7200 Cambridge St, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-9014 , Fax: 713-798-6808 , Email: mitesh.lotia@bcm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Professor of Neurology, Distinguished Chair in Movement Disorders, Director, Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology , Baylor College of Medicine , 7200 Cambridge, Suite 9A, Houston , TX 77030-4202 , Tel: 713-798-5998 , Fax: 713-798-6808 , E-mail: josephj@bcm.edu , Web: www.jankovic.org.</Affiliation></AffiliationInfo></Author><Author><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>ENG</Language><PublicationTypeList><PublicationType UI="">JOURNAL ARTICLE</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>2</Month><Day>1</Day></ArticleDate></Article><MedlineJournalInfo><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Emerging therapies</Keyword><Keyword MajorTopicYN="N">Parkinson</Keyword><Keyword MajorTopicYN="N">amantadine</Keyword><Keyword MajorTopicYN="N">disease modifying therapies</Keyword><Keyword MajorTopicYN="N">levodopa</Keyword><Keyword MajorTopicYN="N">levodopa induced dyskinesia</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">nondopaminergic drug</Keyword><Keyword MajorTopicYN="N">α-synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2016.1149163</ArticleId><ArticleId IdType="pubmed">26830844</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000000 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000000 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26830844
|texte= New and Emerging Medical Therapies in Parkinson's Disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26830844" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |